Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer

par Ciara S. McNevin, Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott, Stephen Finn
Publié 2021

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

par Claire Corcoran, Sweta Rani, Keith O'Brien, Amanda O'Neill, Maria Prencipe, Rizwan Sheikh, Glenn Webb, Ray McDermott, William Watson, John Crown, Lorraine O'Driscoll
Publié 2012